SEC Form 4 · accession 0001445064-16-000240
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Scholz
Officer — Sr. VP, Global Operations
Period of report
Apr 1, 2016
Accepted (ET)
Apr 5, 2016 · 8:36 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Apr 1, 2016 | F | 134 | $64.31 | D | 28,875 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 342 shares acquired between January 7, 2016 and March 3, 2016, under the Mallinckrodt employee stock purchase plan.